^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PPAR γ agonist

    Related drugs:
    4d
    Study on the Characteristics and Cellular Origins of the Sebaceous Gland (ChiCTR2500114709)
    P4, N=20, Not yet recruiting, WUHAN UNIVERSITY; WUHAN UNIVERSITY
    New P4 trial
    |
    rosiglitazone
    7d
    Insulin Regulation of Lipolysis and Lipolysis Proteins (clinicaltrials.gov)
    P1, N=64, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    G0S2 (G0/G1 Switch 2)
    7d
    Repurposing Rosiglitazone Induces Apoptosis Accompanied by Impaired Antioxidant Defense in Cholangiocarcinoma Cells: Findings from Proteomic and Functional Analyses. (PubMed, Pharmaceuticals (Basel))
    Its apoptosis-inducing effect is independent of PPARγ activation. These findings underscore the therapeutic potential of RSG for CCA treatment.
    Journal
    |
    CASP3 (Caspase 3) • ANXA1 (Annexin A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CASP7 (Caspase 7)
    |
    rosiglitazone
    7d
    Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. (PubMed, Int J Mol Sci)
    This allows treatment to be carried out in an outpatient setting, including for elderly and comorbid patients. Triple transcriptional modulation, facilitated by epigenetic modelling with azacitidine, targets reprogramming of non-oncogene addiction networks in AML, re-establishing functionally active, closely interrelated myeloid hallmarks and AML cell death genome-agnostically.
    Review • Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    azacitidine
    1m
    Rbbp7-mediated deacetylation of Acsl4 promotes ovarian aging by enhancing ferroptosis. (PubMed, Int J Biol Macromol)
    We also found that the ferroptosis inhibitor Deferoxamine (DFO), Ferrostatin-1 (Fer-1) or the Acsl4 inhibitor Rosiglitazone (Rosi) inhibited ovarian aging and granulosa cell damage in vivo and in vitro. Inhibiting ferroptosis or Acsl4 can alleviate ovarian aging. Our research has revealed a new mechanism of ovarian aging and provided potential new targets for alleviating it.
    Journal
    |
    ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4)
    |
    rosiglitazone
    1m
    Case Report: Generalized lipodystrophy following immune-checkpoint inhibitor therapy. (PubMed, Front Endocrinol (Lausanne))
    We describe a case of a 48-year-old woman who had been treated with pembrolizumab for lymph node-positive breast cancer. Investigations including a low leptin level and loss of adiposity on whole body composition analysis were consistent with this diagnosis. A trial of pioglitazone was associated with an improvement in insulin resistance and hypertriglyceridemia, although no improvement in her facial lipodystrophy was observed.
    Journal • Checkpoint inhibition
    |
    LEP (Leptin)
    |
    Keytruda (pembrolizumab)
    1m
    Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers (clinicaltrials.gov)
    P1, N=30, Completed, Chong Kun Dang Pharmaceutical
    New P1 trial
    1m
    Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers (clinicaltrials.gov)
    P1, N=31, Completed, Chong Kun Dang Pharmaceutical
    New P1 trial
    1m
    CHIG-MASH: A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    1m
    Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers (clinicaltrials.gov)
    P1, N=30, Completed, Chong Kun Dang Pharmaceutical
    New P1 trial
    1m
    Electroacupuncture ameliorates skeletal muscle insulin resistance in diabetic rats via PPAR-γ/NF-κB signaling pathway (PubMed, Zhen Ci Yan Jiu)
    EA can ameliorate energy metabolism disorders in T2DM rats, reduce ectopic lipid accumulation in skeletal muscle, and alleviate inflammatory responses, which may be related to the regulation of the PPAR-γ/NF-κB signaling pathway.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • SLC2A4 (Solute Carrier Family 2 Member 4)
    2ms
    A Phase 1 Study of JADE101 in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Jade Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed